Market Applicability							
Market	**DC**	**GA**	**KY**	**MD**	**NJ**	**NY**	**WA**
Applicable	X	X	X	X	X	X	NA

Ocrevus (ocrelizumab)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications	Quantity Limit
Ocrevus (ocrelizumab)	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Ocrevus (ocrelizumab) may be approved if the following criteria are met:

I. Individual has a diagnosis of primary progressive multiple sclerosis (PPMS); **AND**
II. Individual is able to ambulate more than 5 meters (not considered wheelchair bound);

OR

III. Individual has a diagnosis of relapsing multiple sclerosis (RMS) (including clinically isolated syndrome, relapsing-remitting disease or active secondary progressive disease); **AND**
IV. Individual is able to ambulate without aid or rest for at least 100 meters; **AND**
V. If initiating therapy, individual has experienced at least two relapses within the previous two years or one relapse within the previous year.

Ocrevus (ocrelizumab) may not be approved for the following:

I. All other indications not included above; **OR**
II. Individual has active hepatitis B or hepatitis C virus infection or another active infection at initiation of therapy; **OR**
III. Individual has a history of life-threatening infusion reaction to Ocrevus (ocrelizumab);

OR

IV. Individual is using to treat non-active secondary progressive multiple sclerosis; **OR**
V. Individual is using to treat systemic lupus erythematosus; **OR**
VI. Individual is using to treat rheumatoid arthritis; **OR**
VII. Concurrent use with other MS disease modifying agents (including Aubagio, Avonex, Betaseron, Copaxone/ Glatiramer/Glatopa, Extavia, Gilenya, Lemtrada, Mavenclad, Mayzent, Plegridy, Rebif, Tecfidera and Tysabri).

Market Applicability							
Market	**DC**	**GA**	**KY**	**MD**	**NJ**	**NY**	**WA**
Applicable	X	X	X	X	X	X	NA

Key References:

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: July 22, 2019.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
4. Olek MJ, Howard J. Clinical presentation, course and prognosis of multiple sclerosis in adults. Last updated: June 11, 2019. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: July 20, 2019.
5. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis. Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90: 777-788. Available from https://www.aan.com/Guidelines/home/GuidelineDetail/898. Accessed: July 20, 2019.
6. Tarver, M. Kurtzke Expanded Disability Status Scale (EDSS). Department of Veterans Affairs: Multiple Sclerosis Centers for Excellence. Last updated: August 3, 2018. Available at: http://www.va.gov/MS/Professionals/Diagnosis/Kurtzke_Expanded_Disability_Status_Scale.asp. Accessed: August 19, 2019.